<DOC>
	<DOCNO>NCT01922141</DOCNO>
	<brief_summary>This study design compare blood pressure lower efficacy aliskiren , combination aliskiren plus amlodipine , ramipril elderly patient mild moderate hypertension . It also compare long-term safety aliskiren-based regimen ramipril-based regimen</brief_summary>
	<brief_title>Aliskiren Study Safety Efficacy Senior Hypertensives</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Ramipril</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Patients ≥ 65 year age clinical diagnosis essential hypertension Visit 1 . Mean sit SBP ( MSSBP ) ≥ 140 mmHg &lt; 180 mmHg Visit 2/Visit 201 Visit 3 . Absolute MSSBP difference ≤ 20 mmHg Visit 3 Visit immediately prior History hypersensitivity study drug drug similar chemical class . Severe hypertension ( MSSBP ≥ 180 mmHg MSDBP ≥ 110 mmHg ) Visit 1 , Visit 2 , Visit 201 Visit 3 patient self measure blood pressure ( SMBP ) monitor prerandomization period confirm office measurement . Current treatment blocker renin angiotensin aldosterone system ( RAAS ) ( aliskiren , ACE inhibitor , angiotensin receptor blocker aldosterone antagonist ) unable discontinue therapy . Concurrent use antihypertensive medication except stable dose 3 month prior Visit 1 alpha adrenergic blocker benign prostatic hypertrophy ( e.g. , tamsulosin [ Flomax® ] benign prostatic hypertrophy ) , beta blocker angina , beta blocker ophthalmic preparation . Contraindications aliskiren , ramipril , amlodipine , hydrochlorothiazide . Other protocol define inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>High blood pressure , stage 1 2 hypertension</keyword>
</DOC>